FDA greenlights Roche's Polivy, expanding label into first-line DLBCL combo therapy
Roche and Genentech announced Wednesday that the FDA approved its antibody-drug conjugate Polivy, combined with the cancer regimen known as R …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
